Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.55 |
| ▸ | CNR2 | P34972 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089449 | 0.99 | CNR1 (0.53) | CNR1CNR2HTTNPSR1SMN1; SMN2 | |
| SCHEMBL4083665 | 0.83 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL4075655 | 0.82 | CNR1 (0.51) | CNR1 | |
| SCHEMBL4084550 | 0.81 | ALDH1A1 (0.52) | CNR1CNR2HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4079982 | 0.79 | EPHX2 (0.40) | CNR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4079984 | 0.79 | EPHX2 (0.40) | CNR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4075592 | 0.79 | CNR1 (0.66) | CNR1CNR2 | |
| SCHEMBL4075572 | 0.79 | CNR1 (0.52) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL4087413 | 0.78 | CNR1 (0.55) | CNR1CNR2HTTNPSR1SMN1; SMN2 | |
| SCHEMBL4075673 | 0.78 | CNR1 (0.64) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-7504522-B2 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMAITED (GB) | 2007-03-08 | — | — | US | disclosed |
| EP-1620395-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096763-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885HTT 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.